[{"id":"0db89e9b-db2b-43cc-83d7-77deb9d111cd","acronym":"SCOUT","url":"https://clinicaltrials.gov/study/NCT02637687","created_at":"2021-01-17T17:20:37.992Z","updated_at":"2025-02-25T12:26:24.234Z","phase":"Phase 1/2","brief_title":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","source_id_and_acronym":"NCT02637687 - SCOUT","lead_sponsor":"Bayer","biomarkers":" NTRK3 • ETV6 • NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK3 • ETV6 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Vitrakvi (larotrectinib) • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 12/16/2015","start_date":" 12/16/2015","primary_txt":" Primary completion: 07/20/2024","primary_completion_date":" 07/20/2024","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-24"},{"id":"a1cc20b7-e120-4c96-ad2e-1583010cd20c","acronym":"CARE study","url":"https://clinicaltrials.gov/study/NCT04094610","created_at":"2021-01-18T20:02:04.781Z","updated_at":"2025-02-25T14:40:19.057Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","source_id_and_acronym":"NCT04094610 - CARE study","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-14"},{"id":"b7222b36-4294-4a60-9a60-79c17a69cc40","acronym":"MEKiAUTO","url":"https://clinicaltrials.gov/study/NCT04214418","created_at":"2021-01-18T20:31:18.521Z","updated_at":"2024-07-02T16:35:17.433Z","phase":"Phase 1/2","brief_title":"Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies","source_id_and_acronym":"NCT04214418 - MEKiAUTO","lead_sponsor":"Columbia University","biomarkers":" KRAS • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • MSI-H/dMMR • NTRK positive • NTRK fusion","tags":["KRAS • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • MSI-H/dMMR • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 02/12/2020","start_date":" 02/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-28"},{"id":"27251627-9d01-4563-9673-f9cf20febcad","acronym":"","url":"https://clinicaltrials.gov/study/NCT05793281","created_at":"2023-03-31T15:02:54.101Z","updated_at":"2025-02-25T17:12:29.001Z","phase":"","brief_title":"An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan","source_id_and_acronym":"NCT05793281","lead_sponsor":"Bayer","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"],"overall_status":"Completed","enrollment":" Enrollment 46621","initiation":"Initiation: 03/10/2023","start_date":" 03/10/2023","primary_txt":" Primary completion: 09/28/2023","primary_completion_date":" 09/28/2023","study_txt":" Completion: 09/28/2023","study_completion_date":" 09/28/2023","last_update_posted":"2023-10-25"},{"id":"08544267-425c-42aa-87ee-a72f61d133e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04614740","created_at":"2021-02-22T08:58:34.782Z","updated_at":"2024-07-02T16:35:59.178Z","phase":"Phase 2","brief_title":"The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT04614740","lead_sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VC004"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-12-13"},{"id":"38586fe8-a3bb-493e-ab3e-daaa8e0d3984","acronym":"","url":"https://clinicaltrials.gov/study/NCT05212987","created_at":"2022-01-29T18:05:39.593Z","updated_at":"2024-07-02T16:36:17.854Z","phase":"Phase 1","brief_title":"Study of FCN-098 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT05212987","lead_sponsor":"Fochon Pharmaceuticals, Ltd.","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FCN-098"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 05/08/2024","primary_completion_date":" 05/08/2024","study_txt":" Completion: 10/12/2024","study_completion_date":" 10/12/2024","last_update_posted":"2022-01-28"},{"id":"18f379f2-39c8-4db1-9ff9-c38f81953cc4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04687423","created_at":"2021-01-19T20:48:05.292Z","updated_at":"2024-07-02T16:36:26.187Z","phase":"Phase 2","brief_title":"Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II）","source_id_and_acronym":"NCT04687423","lead_sponsor":"Fochon Pharmaceuticals, Ltd.","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 04/13/2021","start_date":" 04/13/2021","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2021-08-18"}]